Document is current

Any future updates will be listed below

Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”

Crossref DOI link: https://doi.org/10.1007/s40121-022-00727-4

Published Online: 2022-11-22

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark